Denali Therapeutics Inc.(DNLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DNLI Denali Therapeutics Inc.

Closed Good Friday 04-02 16:00:00 EDT

20.65

+0.97

+4.93%

盘后20.80

+0.15+0.73%

19:58 EDT

High20.66	Low18.92	Vol1.63M
Open18.92	D1 Closing19.68	Amplitude8.84%
Mkt Cap3.27B	Tradable Cap2.97B	Total Shares158.59M
T/O33.01M	T/O Rate1.13%	Tradable Shares144.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"DNLI","market":"US","secType":"STK","nameCN":"Denali Therapeutics Inc.","latestPrice":20.65,"timestamp":1775160000000,"preClose":19.68,"halted":0,"volume":1625806,"hourTrading":{"tag":"盘后","latestPrice":20.8,"preClose":20.65,"latestTime":"19:58 EDT","volume":38499,"amount":795038.897,"timestamp":1775174330223,"change":0.15,"changeRate":0.007264,"amplitude":0.007264},"delay":0,"changeRate":0.049288617886178804,"floatShares":144000000,"shares":158591491,"eps":-2.969999,"marketStatus":"Closed Good Friday","change":0.97,"latestTime":"04-02 16:00:00 EDT","open":18.922,"high":20.66,"low":18.92,"amount":33005848.534932,"amplitude":0.088415,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.969999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775462400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1512709200000,"exchange":"NASDAQ","adjPreClose":19.68,"preHourTrading":{"tag":"盘前","latestPrice":18.98,"preClose":19.68,"latestTime":"09:28 EDT","volume":1281,"amount":25148.699603999998,"timestamp":1775136482058,"change":-0.7,"changeRate":-0.035569,"amplitude":0.033028},"postHourTrading":{"tag":"盘后","latestPrice":20.8,"preClose":20.65,"latestTime":"19:58 EDT","volume":38499,"amount":795038.897,"timestamp":1775174330223,"change":0.15,"changeRate":0.007264,"amplitude":0.007264},"volumeRatio":0.6578241552125403,"impliedVol":0.6947,"impliedVolPercentile":0.3705},"requestUrl":"/m/hq/s/DNLI","defaultTab":"news","newsList":[{"id":"2624669881","title":"Denali regains full rights to DNL593 after Takeda ends collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2624669881","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624669881?lang=en_us&edition=fundamental","pubTime":"2026-04-04 01:35","pubTimestamp":1775237738,"startTime":"0","endTime":"0","summary":"Denali regained full rights and control of investigational therapy DNL593 for GRN-related frontotemporal dementia following Takeda decision to terminate collaboration.Termination was driven by strategic considerations, not by efficacy or safety data.Denali plans to continue clinical development of DNL593 independently.Phase 1/2 study enrollment completed with 40 participants; results expected by end of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the original content used to generate this news brief on April 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDLbVg2fY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNLI","BK4139","BK4548","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624966609","title":"Denali Therapeutics Regains Full Rights to Investigational Therapy Dnl593 (Ptv:Pgrn) for Grn-Related Frontotemporal Dementia (Ftd-Grn)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624966609","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624966609?lang=en_us&edition=fundamental","pubTime":"2026-04-04 01:30","pubTimestamp":1775237406,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nFWN40M00C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DNLI","BK4535","BK4548","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624666091","title":"Denali Therapeutics Inc - to Continue Clinical Development of Dnl593 Using Transportvehicle Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2624666091","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624666091?lang=en_us&edition=fundamental","pubTime":"2026-04-04 01:30","pubTimestamp":1775237406,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nFWN40M00C:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","DNLI","BK4548","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624096666","title":"Denali Therapeutics Inc - Results From Phase 1/2 Study in Ftd-Grn Expected by End of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2624096666","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624096666?lang=en_us&edition=fundamental","pubTime":"2026-04-04 01:30","pubTimestamp":1775237406,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nFWN40M00C:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4548","BK4535","DNLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624556899","title":"FDA grants accelerated approval to Denali’s tividenofusp alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=2624556899","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624556899?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:55","pubTimestamp":1774994144,"startTime":"0","endTime":"0","summary":"FDA granted accelerated approval to Denali’s tividenofusp alfa on March 24, 2026.Denali received USD 200 million in gross proceeds on March 27, 2026 tied to closing of transactions under its Royalty Agreement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL8DpnnX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNLI","BK4548","BK4139","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623813195","title":"Denali Therapeutics Inc - Receives $200 Mln in Gross Proceeds on March 27, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2623813195","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623813195?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:33","pubTimestamp":1774960401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J1BV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4535","DNLI","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623601073","title":"Is Denali Therapeutics’ (DNLI) First Brain-Penetrant Biologic Redefining Its Platform Value Proposition?","url":"https://stock-news.laohu8.com/highlight/detail?id=2623601073","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623601073?lang=en_us&edition=fundamental","pubTime":"2026-03-30 10:06","pubTimestamp":1774836375,"startTime":"0","endTime":"0","summary":"Denali Therapeutics announced that the U.S. Food and Drug Administration previously granted accelerated approval for AVLAYAH (tividenofusp alfa-eknm), the first biologic specifically engineered to cross the blood-brain barrier, for treating neurologic manifestations of Hunter syndrome in certain pediatric patients.\nThis approval not only introduces a new enzyme replacement therapy for a rare pediatric disease but also validates Denali’s TransportVehicle platform as an FDA-cleared route to...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/news/is-denali-therapeutics-dnli-first-brain-penetrant-biologic-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/news/is-denali-therapeutics-dnli-first-brain-penetrant-biologic-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DNLI","BK4548","BK4139","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623357047","title":"Stifel Nicolaus Sticks to Its Buy Rating for Denali Therapeutics (DNLI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623357047","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623357047?lang=en_us&edition=fundamental","pubTime":"2026-03-30 02:57","pubTimestamp":1774810625,"startTime":"0","endTime":"0","summary":"In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Denali Therapeutics, with a price target of $41.00. Mattei...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-its-buy-rating-for-denali-therapeutics-dnli-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-its-buy-rating-for-denali-therapeutics-dnli-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","DNLI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622585051","title":"Wedbush Remains a Buy on Denali Therapeutics (DNLI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622585051","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622585051?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:39","pubTimestamp":1774528743,"startTime":"0","endTime":"0","summary":"In a report released today, Laura Chico from Wedbush maintained a Buy rating on Denali Therapeutics, with a price target of $30.00. Chico covers th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-denali-therapeutics-dnli-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-denali-therapeutics-dnli-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DNLI","BK4548","BK4139","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622496008","title":"US FDA Approves Avlayah To Treat Neurologic Manifestations Of Hunter Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2622496008","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622496008?lang=en_us&edition=fundamental","pubTime":"2026-03-26 00:10","pubTimestamp":1774455056,"startTime":"0","endTime":"0","summary":"March 25 (Reuters) - US FDA: :*US FDA - APPROVES AVLAYAH TO TREAT NEUROLOGIC MANIFESTATIONS OF HUNTER SYNDROME*Further company coverage: DNLI.O* ((Reuters.Briefs@thomsonreuters.com;))  ((Reuters Inves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nRSD40Z5PV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","DNLI","BK4139","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622008171","title":"BUZZ-Denali Therapeutics climbs after US FDA approves co's genetic disorder therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2622008171","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622008171?lang=en_us&edition=fundamental","pubTime":"2026-03-26 00:09","pubTimestamp":1774454946,"startTime":"0","endTime":"0","summary":"BUZZ-Denali Therapeutics climbs after US FDA approves co's genetic disorder therapy** Shares of Denali Therapeutics DNLI.O up 3.6% at $21.72 after the U.S. Food and Drug Administration approves co's t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL6N40D14J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNLI","BK4535","BK4139","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622008557","title":"US FDA approves Denali's genetic disorder therapy for children","url":"https://stock-news.laohu8.com/highlight/detail?id=2622008557","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622008557?lang=en_us&edition=fundamental","pubTime":"2026-03-25 23:56","pubTimestamp":1774454190,"startTime":"0","endTime":"0","summary":"UPDATE 3-US FDA approves Denali's genetic disorder therapy for childrenUpdates shares in paragraph 3, adds price in paragraph 7 and analyst comment in paragraph 10By Sneha S K and Kunal Das","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4N40D1JV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNLI","BK4139","BK4535","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622008985","title":"Denali Therapeutics granted FDA approval of AVLAYAH for treatment of MPS II","url":"https://stock-news.laohu8.com/highlight/detail?id=2622008985","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622008985?lang=en_us&edition=fundamental","pubTime":"2026-03-25 23:55","pubTimestamp":1774454141,"startTime":"0","endTime":"0","summary":"Denali Therapeutics (DNLI) announced the U.S. FDA has granted accelerated approval for AVLAYAH, the first FDA-approved biologic specifically design...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/denali-therapeutics-granted-fda-approval-of-avlayah-for-treatment-of-mps-ii-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/denali-therapeutics-granted-fda-approval-of-avlayah-for-treatment-of-mps-ii-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","DNLI","LABU","BK4548","BK4539","LENZ","BK4535","BK4585","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622008354","title":"Denali Therapeutics gains FDA accelerated approval for AVLAYAH in Hunter syndrome; CSF heparan sulfate drops 91% by week 24","url":"https://stock-news.laohu8.com/highlight/detail?id=2622008354","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622008354?lang=en_us&edition=fundamental","pubTime":"2026-03-25 23:51","pubTimestamp":1774453911,"startTime":"0","endTime":"0","summary":"The FDA granted accelerated approval to Denali’s AVLAYAH  to treat neurologic manifestations of Hunter syndrome  in presymptomatic or symptomatic pediatric patients weighing at least 5 kg before advanced neurologic impairment.The approval was based on cerebrospinal fluid heparan sulfate reduction as a surrogate endpoint, including a 91% reduction by week 24 in a Phase 1/2 trial.The FDA also granted Denali a Rare Pediatric Disease Priority Review Voucher in connection with the approval.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL9gmNZr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4588","BK4535","BK4139","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","DNLI","IE00B64PRP62.GBP","LU0314104364.USD","IE00BGHQF748.EUR","BK4585","IE00BKPKM429.USD","BK4548","IE00BN0W2T93.GBP","LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","BK4112","NDAQ","SG9999014021.USD","SG9999014039.USD","SG9999014013.SGD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622400833","title":"Denali Therapeutics Announces U.S. FDA Approval of Avlayah™ (Tividenofusp Alfa-Eknm) for Treatment of Hunter Syndrome (Mps Ii)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622400833","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622400833?lang=en_us&edition=fundamental","pubTime":"2026-03-25 23:50","pubTimestamp":1774453828,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUA7WMTSS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","DNLI","BK4548","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622331008","title":"Denali Therapeutics Inc - Avlayah to Be Available in U.S. Shortly After Approval, Administered Once Weekly","url":"https://stock-news.laohu8.com/highlight/detail?id=2622331008","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622331008?lang=en_us&edition=fundamental","pubTime":"2026-03-25 23:50","pubTimestamp":1774453828,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUA7WMTSS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","DNLI","BK4548","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622100835","title":"Denali Therapeutics Inc - Awarded Rare Pediatric Disease Priority Review Voucher With FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2622100835","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622100835?lang=en_us&edition=fundamental","pubTime":"2026-03-25 23:50","pubTimestamp":1774453828,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUA7WMTSS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4548","DNLI","BK4139","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622088670","title":"Denali Therapeutics Shares up 4.4%; US FDA Approves Co's Genetic Disorder Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2622088670","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622088670?lang=en_us&edition=fundamental","pubTime":"2026-03-25 23:46","pubTimestamp":1774453575,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4N40D1KF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4548","DNLI","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622255070","title":"US FDA - Approves Avlayah to Treat Neurologic Manifestations of Hunter Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2622255070","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622255070?lang=en_us&edition=fundamental","pubTime":"2026-03-25 23:37","pubTimestamp":1774453035,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40D13L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DNLI","BK4139","BK4535","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621703214","title":"Wedbush Remains a Buy on Denali Therapeutics (DNLI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621703214","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621703214?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:19","pubTimestamp":1774268359,"startTime":"0","endTime":"0","summary":"In a report released today, Laura Chico from Wedbush maintained a Buy rating on Denali Therapeutics, with a price target of $30.00. According to Ti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-denali-therapeutics-dnli-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-denali-therapeutics-dnli-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BK4139","DNLI","BK4548"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.denalitherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0464},{"period":"1month","weight":0.0315},{"period":"3month","weight":0.2692},{"period":"6month","weight":0.3392},{"period":"1year","weight":0.5029},{"period":"ytd","weight":0.2508}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":-0.036},{"period":"3month","weight":-0.04},{"period":"6month","weight":-0.02},{"period":"1year","weight":0.1617},{"period":"ytd","weight":-0.0383}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.068767},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.02262},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.087803},{"month":4,"riseRate":0.666667,"avgChangeRate":0.01888},{"month":5,"riseRate":0.75,"avgChangeRate":0.047446},{"month":6,"riseRate":0.625,"avgChangeRate":0.059984},{"month":7,"riseRate":0.375,"avgChangeRate":-0.046178},{"month":8,"riseRate":0.625,"avgChangeRate":0.067423},{"month":9,"riseRate":0.5,"avgChangeRate":0.021936},{"month":10,"riseRate":0.375,"avgChangeRate":-0.037447},{"month":11,"riseRate":0.625,"avgChangeRate":0.13715},{"month":12,"riseRate":0.375,"avgChangeRate":0.011033}],"exchange":"NASDAQ","name":"Denali Therapeutics Inc.","nameEN":"Denali Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Denali Therapeutics Inc.(DNLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Denali Therapeutics Inc.(DNLI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Denali Therapeutics Inc.,DNLI,Denali Therapeutics Inc.股票,Denali Therapeutics Inc.股票老虎,Denali Therapeutics Inc.股票老虎国际,Denali Therapeutics Inc.行情,Denali Therapeutics Inc.股票行情,Denali Therapeutics Inc.股价,Denali Therapeutics Inc.股市,Denali Therapeutics Inc.股票价格,Denali Therapeutics Inc.股票交易,Denali Therapeutics Inc.股票购买,Denali Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Denali Therapeutics Inc.(DNLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Denali Therapeutics Inc.(DNLI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}